Study dataset
Targeted tumor sequencing with MSI status and actionable mutation calls.
Listed May 5, 2026
The MSK-IMPACT Endometrial Cancer cohort is a large-scale, prospective genomic study of over 1,800-2,400+ patients with endometrial cancer, used to identify actionable somatic mutations and MSI status via the 505-gene MSK-IMPACT test. This database often covers key subtypes like endometrioid and serous, with findings showing roughly 68% of cases have actionable alterations.
Actionable Findings
MSK-IMPACT analysis of endometrial cancers reveals actionable mutations in 68% of patients, with about 27% enrolling in matched clinical trials.
Genomic Alterations
Studies frequently identify PTEN, PIK3CA, ARID1A, TP53, and POLE mutations. The cohort highlighted that TP53 mutations are higher in this cohort compared to TCGA data, while PTEN alterations are lower.
MSI and Lynch Syndrome
Microsatellite instability (MSI-H) is used to detect Lynch syndrome-associated cancers, aiding in germline cancer predisposition screenings.
Key Datasets
The data is often cited as the Endometrial Cancer (MSK, 2018), Endometrial Cancer (MSK, Cancer Discovery 2023), and as part of the MSK-IMPACT 50K Clinical Sequencing Cohort (2026).
Molecular Subtypes
The cohort includes detailed genomic profiles of uterine endometrioid carcinoma, serous carcinoma, and carcinosarcoma, allowing for characterization of POLE-mutated and MSI-H